BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, March 25, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 27, 2020
View Archived Issues
Early roots of ALS visible in teeth
Read More
Can N-BPs become MVP again?
Read More
IL-10 upregulation with AD-110 improves cognition and stroke deficits in animal studies
Read More
FDA clears IND application for phase I study of Q-702
Read More
FDA gives accelerated response to proposed TSC COVID-19 clinical program
Read More
Sorrento receives FDA clearance to initiate a phase I study of STI-6129 in amyloidosis
Read More
ATx-201 found safe and able to improve skin barrier function biomarkers in phase II study
Read More
LFS-829 significantly reverses the pathological features of colitis in vivo
Read More
Surprise suggestion for CAR T neurotoxicity culprit
Read More
Gilead identifies new integrin alpha4beta7 antagonists
Read More
Atara Biotherapeutics presents phase I data on ATA-188 in patients with progressive MS
Read More
Merck & Co. patents IDO-1 inhibitors
Read More
New Mcl-1 inhibitors disclosed by Prelude Therapeutics
Read More
Dana-Farber Cancer Institute presents new JAK2 inhibitors
Read More
GPR139 receptor modulators discovered at BlackThorn Therapeutics
Read More
PRIMVAC placental malaria vaccine immunogenic but shows limited cross-reactivity in trial
Read More
Topline phase Ib results support further development of DUR-928 in NASH
Read More
Phase III Archway study of Port Delivery System with ranibizumab in wet AMD meets primary endpoint
Read More
FDA approves Dupixent for moderate to severe atopic dermatitis in children aged 6-11 years
Read More
Arena updates progress of etrasimod and other pipeline programs
Read More
Innovent begins phase I trial in China with anti-TIGIT antibody IBI-939
Read More
New phase I/II trial explores next-generation lytic immunotherapy CyPep-1 in advanced solid tumors
Read More
